NeuroMetrix Inc Total Liabilities
NeuroMetrix Inc total liabilities. Based on the latest financial reports, NeuroMetrix Inc (NURO) has total liabilities worth $1.01 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of NeuroMetrix Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of NeuroMetrix Inc (2002–2024)
Total liabilities of NeuroMetrix Inc from 2002 to 2024. This chart illustrates how NeuroMetrix Inc's total liabilities have evolved over time, based on quarterly financial data.
NeuroMetrix Inc Competitors by Total Liabilities
The table below lists competitors of NeuroMetrix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fortune Rise Acquisition Corp
NASDAQ:FRLA
|
USA | $11.37 Million |
|
HK Metals Utama Tbk PT
JK:HKMU
|
Indonesia | Rp467.59 Billion |
|
Ostasiatiske Kompagni A/S
CO:OKEAC
|
Denmark | Dkr300.00K |
|
Polygiene AB
ST:POLYG
|
Sweden | Skr24.66 Million |
|
China Aoyuan Group Limited
F:47C
|
Germany | €173.87 Billion |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $1.83 Million |
|
NetX Holdings Bhd
KLSE:0020
|
Malaysia | RM34.86 Million |
|
Ease2pay NV
AS:EAS2P
|
Netherlands | €3.21 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down NeuroMetrix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NURO total asset value.
Liquidity & Leverage Metrics
NeuroMetrix Inc Total Liabilities Ratios Explained
NeuroMetrix Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NeuroMetrix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NeuroMetrix Inc (2002–2024)
The table below shows the annual total liabilities of NeuroMetrix Inc from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.01 Million | -24.05% |
| 2023-12-31 | $1.33 Million | +1.46% |
| 2022-12-31 | $1.31 Million | -21.43% |
| 2021-12-31 | $1.67 Million | -39.11% |
| 2020-12-31 | $2.75 Million | -37.05% |
| 2019-12-31 | $4.36 Million | -27.46% |
| 2018-12-31 | $6.02 Million | +31.29% |
| 2017-12-31 | $4.58 Million | +37.88% |
| 2016-12-31 | $3.32 Million | -4.28% |
| 2015-12-31 | $3.47 Million | -56.68% |
| 2014-12-31 | $8.02 Million | +122.53% |
| 2013-12-31 | $3.60 Million | +73.41% |
| 2012-12-31 | $2.08 Million | -33.69% |
| 2011-12-31 | $3.13 Million | +9.23% |
| 2010-12-31 | $2.87 Million | -40.96% |
| 2009-12-31 | $4.86 Million | -43.17% |
| 2008-12-31 | $8.55 Million | -11.39% |
| 2007-12-31 | $9.64 Million | -21.57% |
| 2006-12-31 | $12.30 Million | +84.96% |
| 2005-12-31 | $6.65 Million | +70.65% |
| 2004-12-31 | $3.90 Million | -92.61% |
| 2003-12-31 | $52.72 Million | +12.21% |
| 2002-12-31 | $46.98 Million | -- |
About NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endoc… Read more